Form 4 for IGC IGC Pharma, Inc.

Accepted 2021-12-23 00:00:00 ET · period of report 2021-12-20 · accession 0001185185-21-001874 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-12-23	2021-12-20	IGC	GRIMALDI CLAUDIA	VP, PFO	A - Grant	$0.00	+250.0K	438.0K	+133%	$0
DM	2021-12-23	2021-12-20	IGC	GRIMALDI CLAUDIA	VP, PFO	A - Grant	$0.00	+400.0K	400.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-12-20	A	A	250,000	$0.00	437,987	D	—	—	(F1) Restricted shares of common stock equally vesting over three years starting March 31, 2022, previously reported on Form 4 Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned. (F2) Corrects ownership amount of all previous Section 16 filings of the Reporting Person since May 14, 2021, which overstated the non-derivative securities ownership by 250,000 shares.
2	Derivative	Restricted Stock Units	2021-12-20	A	A	250,000	$0.00	250,000	D	$0.00 · 2022-03-31 to 2024-04-01	250,000 Common Stock	(F1) Restricted shares of common stock equally vesting over three years starting March 31, 2022, previously reported on Form 4 Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned.
3	Derivative	Restricted Stock Units	2021-12-20	A	A	150,000	$0.00	400,000	D	$0.00 · — to —	150,000 Common Stock	(F3) Restricted shares of common stock subject to vesting according to specific milestones set by the Company's Board of Directors. (F4) Restricted shares of common stock do not have an exercisable or expiration date. The RSUs vest when milestones are achieved.